{"id":"amprenavir","rwe":[{"pmid":"41826234","year":"2026","title":"Modulation of Pepsin-Mediated Inflammatory Responses in Vocal Cord Epithelial Cells by Amprenavir.","finding":"","journal":"The Laryngoscope","studyType":"Clinical Study"},{"pmid":"41642702","year":"2026","title":"Drug Repurposing: Conversion of the Peripherally Restricted HIV Protease Inhibitor Amprenavir to Potent, Selective, and CNS-Penetrant Agonists for the Cannabinoid Receptor 2.","finding":"","journal":"Journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"41600559","year":"2025","title":"Insights into Transport Function of the Murine Organic Anion-Transporting Polypeptide OATP1B2 by Comparison with Its Rat and Human Orthologues.","finding":"","journal":"Toxics","studyType":"Clinical Study"},{"pmid":"41304794","year":"2025","title":"Classifying Effluxable Versus Non-Effluxable Compounds Using a Permeability Threshold Based on Fundamental Energy Constraints.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"40914997","year":"2026","title":"Structure-based drug design; Computational strategies in drug discovery; Antihypertensive agents; Antiviral drugs; Molecular docking; QSAR; Pharmacological insights.","finding":"","journal":"Computational biology and chemistry","studyType":"Clinical Study"}],"tags":[{"label":"Protease Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 3A4","category":"target"},{"label":"CYP3A4","category":"gene"},{"label":"TBXAS1","category":"gene"},{"label":"CTSD","category":"gene"},{"label":"J05AE05","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Human immunodeficiency virus infection","category":"indication"},{"label":"Glaxosmithkline","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-HIV Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Retroviral Agents","category":"pharmacology"},{"label":"Antibiotics, Antitubercular","category":"pharmacology"},{"label":"Antitubercular Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"HIV Protease Inhibitors","category":"pharmacology"},{"label":"Protease Inhibitors","category":"pharmacology"},{"label":"Viral Protease Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":278.158,"date":"","count":45,"signal":"Viral mutation identified","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=278)"},{"llr":240.531,"date":"","count":42,"signal":"Virologic failure","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=241)"},{"llr":211.157,"date":"","count":41,"signal":"Pathogen resistance","source":"DrugCentral FAERS","actionTaken":"Reported 41 times (LLR=211)"}],"drugInteractions":[{"url":"/drug/atorvastatin","drug":"atorvastatin","action":"Monitor closely","effect":"May interact with Atorvastatin Calcium","source":"DrugCentral","drugSlug":"atorvastatin"},{"url":"/drug/bepridil","drug":"bepridil","action":"Avoid combination","effect":"May interact with Bepridil","source":"DrugCentral","drugSlug":"bepridil"},{"url":"/drug/bosentan","drug":"bosentan","action":"Monitor closely","effect":"May interact with Bosentan","source":"DrugCentral","drugSlug":"bosentan"},{"url":"/drug/cerivastatin","drug":"cerivastatin","action":"Monitor closely","effect":"May interact with Cerivastatin Sodium","source":"DrugCentral","drugSlug":"cerivastatin"},{"url":"/drug/cisapride","drug":"cisapride","action":"Avoid combination","effect":"May interact with Cisapride","source":"DrugCentral","drugSlug":"cisapride"},{"url":"/drug/clomipramine","drug":"clomipramine","action":"Monitor closely","effect":"May interact with Clomipramine","source":"DrugCentral","drugSlug":"clomipramine"},{"url":"/drug/clozapine","drug":"clozapine","action":"Monitor closely","effect":"May interact with Clozapine","source":"DrugCentral","drugSlug":"clozapine"},{"url":"/drug/desogestrel","drug":"desogestrel","action":"Avoid combination","effect":"May interact with Desogestrel","source":"DrugCentral","drugSlug":"desogestrel"},{"url":"/drug/doxepin","drug":"doxepin","action":"Monitor closely","effect":"May interact with Doxepin","source":"DrugCentral","drugSlug":"doxepin"},{"url":"/drug/ergotamine","drug":"ergotamine","action":"Avoid combination","effect":"May interact with Ergotamine Tartrate","source":"DrugCentral","drugSlug":"ergotamine"},{"url":"/drug/erythromycin","drug":"erythromycin","action":"Monitor closely","effect":"May interact with Erythromycin","source":"DrugCentral","drugSlug":"erythromycin"},{"url":"/drug/estradiol","drug":"estradiol","action":"Monitor closely","effect":"May interact with Estradiol","source":"DrugCentral","drugSlug":"estradiol"},{"url":"/drug/estrone","drug":"estrone","action":"Monitor closely","effect":"May interact with Estrone","source":"DrugCentral","drugSlug":"estrone"},{"url":"/drug/estropipate","drug":"estropipate","action":"Monitor closely","effect":"May interact with Estropipate","source":"DrugCentral","drugSlug":"estropipate"},{"url":"/drug/ethinylestradiol","drug":"ethinylestradiol","action":"Monitor closely","effect":"May interact with Ethinyl Estradiol","source":"DrugCentral","drugSlug":"ethinylestradiol"},{"url":"/drug/etonogestrel","drug":"etonogestrel","action":"Monitor closely","effect":"May interact with Etonogestrel","source":"DrugCentral","drugSlug":"etonogestrel"},{"url":"/drug/imipramine","drug":"imipramine","action":"Monitor closely","effect":"May interact with Imipramine","source":"DrugCentral","drugSlug":"imipramine"},{"url":"/drug/ixabepilone","drug":"ixabepilone","action":"Monitor closely","effect":"May interact with Ixabepilone","source":"DrugCentral","drugSlug":"ixabepilone"},{"url":"/drug/levonorgestrel","drug":"levonorgestrel","action":"Monitor closely","effect":"May interact with Levonorgestrel","source":"DrugCentral","drugSlug":"levonorgestrel"},{"url":"/drug/lidocaine","drug":"lidocaine","action":"Monitor closely","effect":"May interact with Lidocaine","source":"DrugCentral","drugSlug":"lidocaine"}],"commonSideEffects":[],"contraindications":["Acquired hemolytic anemia","Autoimmune hemolytic anemia","Blood coagulation disorder","Breastfeeding (mother)","Cardiovascular event risk","Chronic hepatitis C","Chronic type B viral hepatitis","Diabetes mellitus","Disease of liver","Disorder of coronary artery","Familial hypercholesterolemia - homozygous","Hemolytic anemia","Hereditary factor IX deficiency disease","Hereditary factor VIII deficiency disease","Hypercholesterolemia","Hyperglycemia","Hypertensive disorder","Hypertriglyceridemia","Ketoacidosis in diabetes mellitus","Kidney stone","Lipodystrophy","Liver function tests abnormal","Myocardial infarction","Obesity","Smokes tobacco daily"]},"trials":[],"aliases":[],"company":"GSK","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AMPRENAVIR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:00:41.518517+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:00:48.062665+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:00:41.590803+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMPRENAVIR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:00:48.370854+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Human immunodeficiency virus type 1 protease inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:00:49.530902+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL116/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:00:49.103081+00:00"}},"allNames":"agenerase","offLabel":[],"synonyms":["amprenavir","agenerase","angenerase","samprenavir"],"timeline":[{"date":"1999-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from GLAXOSMITHKLINE to Glaxosmithkline"},{"date":"1999-04-15","type":"positive","source":"DrugCentral","milestone":"FDA approval (Glaxosmithkline)"},{"date":"2000-10-20","type":"positive","source":"DrugCentral","milestone":"EMA approval"}],"aiSummary":"Agenerase (amprenavir) is a protease inhibitor, a type of antiretroviral medication, originally developed by GlaxoSmithKline and currently owned by the same company. It targets the cytochrome P450 3A4 enzyme and is used to treat human immunodeficiency virus (HIV) infection. Agenerase was FDA-approved in 1999 and is now off-patent, meaning it is no longer protected by active patents. As a result, there are currently no generic manufacturers of the drug. Despite its off-patent status, Agenerase remains a commercial product.","brandName":"Agenerase","ecosystem":[{"indication":"Human immunodeficiency virus infection","otherDrugs":[{"name":"abacavir","slug":"abacavir","company":"Viiv Hlthcare"},{"name":"atazanavir","slug":"atazanavir","company":"Bristol Myers Squibb"},{"name":"bictegravir","slug":"bictegravir","company":"Gilead Sciences Inc"},{"name":"cobicistat","slug":"cobicistat","company":"Gilead Sciences Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Cytochrome P450 3A4","novelty":"Follow-on","targets":[{"gene":"CYP3A4","source":"DrugCentral","target":"Cytochrome P450 3A4","protein":"Cytochrome P450 3A4"},{"gene":"TBXAS1","source":"DrugCentral","target":"Thromboxane-A synthase","protein":"Thromboxane-A synthase"},{"gene":"CTSD","source":"DrugCentral","target":"Cathepsin D","protein":"Cathepsin D"}],"moaClass":"Cytochrome P450 3A4 Inducers","modality":"Small Molecule","drugClass":"Protease Inhibitor","explanation":"","oneSentence":"","technicalDetail":"Agenerase (amprenavir) is a small molecule protease inhibitor that selectively binds to the active site of the HIV protease enzyme, thereby inhibiting its catalytic activity and preventing the maturation of viral particles."},"commercial":{"launchDate":"1999","_launchSource":"DrugCentral (FDA 1999-04-15, GLAXOSMITHKLINE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/200","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AMPRENAVIR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMPRENAVIR","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T08:47:24.010638","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:00:50.777373+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"saquinavir","drugSlug":"saquinavir","fdaApproval":"1995-12-06","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"indinavir","drugSlug":"indinavir","fdaApproval":"1996-03-13","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ritonavir","drugSlug":"ritonavir","fdaApproval":"1996-03-01","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nelfinavir","drugSlug":"nelfinavir","fdaApproval":"1997-03-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"fosamprenavir","drugSlug":"fosamprenavir","fdaApproval":"2003-10-20","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"atazanavir","drugSlug":"atazanavir","fdaApproval":"2003-06-20","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tipranavir","drugSlug":"tipranavir","fdaApproval":"2005-06-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"darunavir","drugSlug":"darunavir","fdaApproval":"2006-06-23","patentExpiry":"Jun 26, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nirmatrelvir","drugSlug":"nirmatrelvir","fdaApproval":"2023-05-25","relationship":"same-class"}],"genericName":"amprenavir","indications":{"approved":[{"name":"Human immunodeficiency virus infection","source":"DrugCentral","snomedId":86406008,"regulator":"FDA"}],"offLabel":[{"name":"Prevention of HIV Infection after Exposure","source":"DrugCentral","drugName":"AMPRENAVIR","evidenceCount":3,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Glaxosmithkline","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"saquinavir","brandName":"saquinavir","genericName":"saquinavir","approvalYear":"1995","relationship":"same-class"},{"drugId":"indinavir","brandName":"indinavir","genericName":"indinavir","approvalYear":"1996","relationship":"same-class"},{"drugId":"ritonavir","brandName":"ritonavir","genericName":"ritonavir","approvalYear":"1996","relationship":"same-class"},{"drugId":"nelfinavir","brandName":"nelfinavir","genericName":"nelfinavir","approvalYear":"1997","relationship":"same-class"},{"drugId":"fosamprenavir","brandName":"fosamprenavir","genericName":"fosamprenavir","approvalYear":"2003","relationship":"same-class"},{"drugId":"atazanavir","brandName":"atazanavir","genericName":"atazanavir","approvalYear":"2003","relationship":"same-class"},{"drugId":"tipranavir","brandName":"tipranavir","genericName":"tipranavir","approvalYear":"2005","relationship":"same-class"},{"drugId":"darunavir","brandName":"darunavir","genericName":"darunavir","approvalYear":"2006","relationship":"same-class"},{"drugId":"nirmatrelvir","brandName":"nirmatrelvir","genericName":"nirmatrelvir","approvalYear":"2023","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":["HIV Infections"],"enrollment":1578,"completionDate":"2020-09-30"},{"nctId":"NCT00056641","phase":"PHASE2","title":"Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02-18","conditions":["HIV Infections"],"enrollment":328,"completionDate":""},{"nctId":"NCT00071760","phase":"PHASE2","title":"Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2003-10-23","conditions":["Infection, Human Immunodeficiency Virus","HIV Infections"],"enrollment":59,"completionDate":"2022-03-29"},{"nctId":"NCT00039741","phase":"PHASE2,PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":["HIV Infections"],"enrollment":266,"completionDate":"2010-03"},{"nctId":"NCT00001085","phase":"PHASE2","title":"A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":94,"completionDate":"1998-09"},{"nctId":"NCT00001095","phase":"PHASE2","title":"A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":94,"completionDate":"1999-10"},{"nctId":"NCT00006152","phase":"PHASE2","title":"A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":42,"completionDate":"2002-08"},{"nctId":"NCT00005762","phase":"NA","title":"Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-03","conditions":["HIV Infections"],"enrollment":90,"completionDate":"2004-05"},{"nctId":"NCT00001133","phase":"PHASE1","title":"Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":50,"completionDate":"2006-08"},{"nctId":"NCT00000940","phase":"PHASE2","title":"Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1999-05","conditions":["HIV Infections"],"enrollment":121,"completionDate":"2006-10"},{"nctId":"NCT00000912","phase":"PHASE2","title":"A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":475,"completionDate":"2000-05"},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":["HIV Infections"],"enrollment":675,"completionDate":"2009-12"},{"nctId":"NCT01077557","phase":"","title":"Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2006-11","conditions":["Fracture","Infection, Human Immunodeficiency Virus"],"enrollment":1,"completionDate":"2011-11"},{"nctId":"NCT00089583","phase":"PHASE2","title":"48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2004-07","conditions":["Infection, Human Immunodeficiency Virus I"],"enrollment":110,"completionDate":"2013-07"},{"nctId":"NCT00040664","phase":"PHASE2","title":"A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2002-07","conditions":["HIV Infection"],"enrollment":69,"completionDate":"2008-10"},{"nctId":"NCT00240552","phase":"PHASE4","title":"Fosamprenavir Expanded Access","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2003-07","conditions":["Infection, Human Immunodeficiency Virus"],"enrollment":85,"completionDate":"2005-08"},{"nctId":"NCT00802074","phase":"NA","title":"An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-12","conditions":["Healthy"],"enrollment":45,"completionDate":"2009-04"},{"nctId":"NCT00614991","phase":"NA","title":"An Interaction Study to Assess Drug Levels in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-01","conditions":["Healthy"],"enrollment":44,"completionDate":"2008-03"},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":["HIV-1 Infection"],"enrollment":482,"completionDate":"2014-10"},{"nctId":"NCT00006617","phase":"NA","title":"Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":25,"completionDate":"2007-06"},{"nctId":"NCT00006578","phase":"NA","title":"Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT02182765","phase":"PHASE1","title":"Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"1999-04","conditions":["HIV Infections"],"enrollment":8,"completionDate":""},{"nctId":"NCT00624195","phase":"PHASE2,PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":["HIV Infections"],"enrollment":59,"completionDate":"2012-06"},{"nctId":"NCT00148785","phase":"PHASE4","title":"A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-07","conditions":["HIV Infections"],"enrollment":15,"completionDate":"2007-01"},{"nctId":"NCT00335270","phase":"PHASE4","title":"A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-03","conditions":["HIV"],"enrollment":100,"completionDate":"2007-12"},{"nctId":"NCT00296504","phase":"PHASE3","title":"A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2001-11","conditions":["Infection, Human Immunodeficiency Virus"],"enrollment":753,"completionDate":"2010-10"},{"nctId":"NCT00000919","phase":"NA","title":"A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":900,"completionDate":"2002-11"},{"nctId":"NCT00000918","phase":"PHASE2","title":"A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":"2002-02"},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":["HIV-Associated Lipodystrophy Syndrome","Cardiovascular Disease"],"enrollment":80,"completionDate":"2007-12"},{"nctId":"NCT01054638","phase":"","title":"HIV Treatment and CVD Events","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-03","conditions":["HIV Infection","Cardiovascular Disease","Infection, Human Immunodeficiency Virus","Acute Myocardial Infarction"],"enrollment":0,"completionDate":"2010-12"},{"nctId":"NCT00001119","phase":"NA","title":"Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1999-10","conditions":["HIV Infections"],"enrollment":288,"completionDate":""},{"nctId":"NCT00046033","phase":"PHASE2","title":"Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":118,"completionDate":""},{"nctId":"NCT00259727","phase":"","title":"The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2006-01","conditions":["Diabetes","HIV Infections","Insulin Resistance"],"enrollment":80,"completionDate":"2008-09"},{"nctId":"NCT00481182","phase":"PHASE1","title":"Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02","conditions":["Healthy Subjects"],"enrollment":20,"completionDate":""},{"nctId":"NCT00038532","phase":"PHASE2","title":"Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART","status":"COMPLETED","sponsor":"Abbott","startDate":"2001-04","conditions":["HIV Infections"],"enrollment":24,"completionDate":""},{"nctId":"NCT00001758","phase":"PHASE2","title":"Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1997-11","conditions":["HIV Infection"],"enrollment":25,"completionDate":"2003-08"},{"nctId":"NCT00001968","phase":"PHASE1","title":"Once-Daily Drug Regimen for HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-01","conditions":["Acquired Immunodeficiency Syndrome","HIV Infections"],"enrollment":25,"completionDate":"2000-11"},{"nctId":"NCT00001766","phase":"PHASE1","title":"Drug Interactions Among Anti-HIV Agents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1998-08","conditions":["HIV Infection"],"enrollment":22,"completionDate":"2003-08"},{"nctId":"NCT00038519","phase":"PHASE2,PHASE3","title":"Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor","status":"COMPLETED","sponsor":"Abbott","startDate":"2001-04","conditions":["HIV Infections"],"enrollment":16,"completionDate":""},{"nctId":"NCT00002239","phase":"PHASE2","title":"A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"1999-05","conditions":["HIV Infections"],"enrollment":68,"completionDate":""},{"nctId":"NCT00196625","phase":"PHASE2","title":"Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2000-11","conditions":["HIV Infections"],"enrollment":100,"completionDate":"2002-02"},{"nctId":"NCT00002213","phase":"PHASE2","title":"The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":80,"completionDate":""},{"nctId":"NCT00002426","phase":"NA","title":"A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"","conditions":["HIV Infections"],"enrollment":390,"completionDate":""},{"nctId":"NCT00006591","phase":"NA","title":"Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment","status":"UNKNOWN","sponsor":"Gathe, Joseph, M.D.","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002419","phase":"PHASE2","title":"Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"","conditions":["HIV Infections"],"enrollment":25,"completionDate":""},{"nctId":"NCT00002417","phase":"NA","title":"A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002245","phase":"PHASE3","title":"A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-04","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002183","phase":"PHASE1","title":"A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":60,"completionDate":""},{"nctId":"NCT00005017","phase":"PHASE4","title":"Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment","status":"UNKNOWN","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":""},{"nctId":"NCT00002423","phase":"PHASE2","title":"A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-03","conditions":["HIV Infections"],"enrollment":100,"completionDate":""},{"nctId":"NCT00002202","phase":"PHASE3","title":"A Comparison of 141W94 and Indinavir in HIV-Infected Patients","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":460,"completionDate":""},{"nctId":"NCT00002217","phase":"NA","title":"A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002216","phase":"NA","title":"A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002372","phase":"PHASE1","title":"A Study of 141W94 in Combination With Other Anti-HIV Drugs","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":48,"completionDate":""},{"nctId":"NCT00002405","phase":"NA","title":"A Study of Amprenavir in HIV-Infected Patients","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002193","phase":"PHASE3","title":"Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":210,"completionDate":""},{"nctId":"NCT00002440","phase":"PHASE2","title":"A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":80,"completionDate":""},{"nctId":"NCT00002205","phase":"NA","title":"An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002233","phase":"PHASE2","title":"A Study of a Combination of Four Drugs in Patients With Recent HIV Infection","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":30,"completionDate":""},{"nctId":"NCT00002195","phase":"PHASE3","title":"A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":["HIV Infections"],"enrollment":290,"completionDate":""}],"_emaApprovals":[{"date":"2000-10-20","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000148609","MMSL":"29919","NDDF":"007752","UNII":"5S0W860XNR","VUID":"4021158","CHEBI":"CHEBI:40050","VANDF":"4021158","INN_ID":"7751","RXNORM":"228655","UMLSCUI":"C0754188","chemblId":"CHEMBL116","ChEMBL_ID":"CHEMBL116","KEGG_DRUG":"D00894","DRUGBANK_ID":"DB00701","PDB_CHEM_ID":" 478","PUBCHEM_CID":"65016","SNOMEDCT_US":"116088006","IUPHAR_LIGAND_ID":"12681","MESH_SUPPLEMENTAL_RECORD_UI":"C095108"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1999-","companyName":"GSK","relationship":"Original Developer"}],"publicationCount":790,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"J05AE05","allCodes":["J05AE05"]},"biosimilarFilings":[],"originalDeveloper":"Glaxosmithkline","recentPublications":[{"date":"2026 Mar 13","pmid":"41826234","title":"Modulation of Pepsin-Mediated Inflammatory Responses in Vocal Cord Epithelial Cells by Amprenavir.","journal":"The Laryngoscope"},{"date":"2026 Feb 26","pmid":"41642702","title":"Drug Repurposing: Conversion of the Peripherally Restricted HIV Protease Inhibitor Amprenavir to Potent, Selective, and CNS-Penetrant Agonists for the Cannabinoid Receptor 2.","journal":"Journal of medicinal chemistry"},{"date":"2025 Dec 20","pmid":"41600559","title":"Insights into Transport Function of the Murine Organic Anion-Transporting Polypeptide OATP1B2 by Comparison with Its Rat and Human Orthologues.","journal":"Toxics"},{"date":"2025 Nov 11","pmid":"41304794","title":"Classifying Effluxable Versus Non-Effluxable Compounds Using a Permeability Threshold Based on Fundamental Energy Constraints.","journal":"Pharmaceutics"},{"date":"2026 Feb","pmid":"40914997","title":"Structure-based drug design; Computational strategies in drug discovery; Antihypertensive agents; Antiviral drugs; Molecular docking; QSAR; Pharmacological insights.","journal":"Computational biology and chemistry"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Glaxosmithkline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"1999","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:00:50.777373+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}